News

Celon Pharma S.A. at the JP Morgan Investor Conference 2020

This year’s conference will be held between 13 and 16 January 2020 in San Francisco. Representatives of the Company’s Management Board will participate in the event. Maciej Wieczorek, CEO of Celon Pharma S.A.: This year, we are focusing on continuing the talks regarding a partnership agreement for esketamine DPI. The schedule of the phase IIRead more »

Innovators’ Breakfast with Celon Pharma S.A.

Dr. Maciej Wieczorek participated in the Innovators’ Breakfast at the invitation of the Ministry of Science and Higher Education and the National Centre for Research and Development. The purpose of the meeting was to inaugurate the “Fast Path” contest, but also to discuss the directions of the development of innovative economy in 2020 and theRead more »

Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen

  During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will takeRead more »

Celon Pharma – leader of the European Life Science training project

Celon Pharma became the leader of a European training project concerning the so-called hard skills, addressed to scientists, students, start-ups and entrepreneurs from all over Europe. The project is implemented in cooperation with the Medical University in Łódź, University of Navarra and Universidade de Evora, within the EIT Health network. Maciej Wieczorek, CEO of CelonRead more »

Valzek – drug status update

By way of decisions of the Chief Pharmaceutical Inspectorate of 6/06/2019, the following drug batches mentioned therein – Valzek 80mg and Valzek 160mg – were re-approved for marketing, as a result of confirming their compliance with quality requirements for the applicable substance valsartan, determined by the regulators. Based on these decisions, batches of Valzek markedRead more »

Celon Pharma at the BIO International Convention 2019

The Company’s representatives will participate in the BIO International Convention 2019, an international convention which attracts over 16.000 biotechnology and pharmacy leaders each year. The conference allows for networking and collaboration in the field of drug development. Maciej Wieczorek, CEO of Celon Pharma S.A.: We can confirm the growing interest in our projects in theRead more »

FDA approved FGFR as new and validated molecular aim in cancer treatment

On 12 April 2019, the Food and Drug Administration (FDA) allowed the marketing of erdafitinib in urinary tract cancer treatment. This decision confirms the great potential of FGFR inhibitors in various solid cancers with FGFR aberrations and proves the recognition of this class medicines as new tools in advanced solid cancers treatment. Celon Pharma S.A.Read more »

#EPA2019 – presentation of the Company’s scientific and research projects as well as its generic portfolio during the most important event of European psychiatry

Celon Pharma S.A. representatives took part in the 27th European Congress of Psychiatry, EPA 2019, which was held from 6 to 9 April 2019 in Warsaw. Over 3,500 participants from all over the world took part in workshops, lectures and presentations devoted to the latest achievements in neuropsychiatry. The European Psychiatric Association is the biggestRead more »

Celon Pharma S.A. on #GPWInnovationDay 2019 on the way to a neuropsychiatric blockbuster

Representatives of the Company’s Management Board: Bogdan Manowski – Director for Business Development and dr Maciej Wieczorek – President of the Management Board, spoke at the GPW Innovation Day conference which is a meeting of investors with innovative companies including companies from biotechnology sector. During their presentation, the Management Board presented the current status ofRead more »

Celon Pharma increases the chances for a neuropsychiatric blockbuster and increases its export rates

Three active clinical programmes, including two regarding the most dynamic therapeutic area from the point of view of the next decade, which is neuropsychiatry, advanced pre-clinical development of drug candidates with innovative potential, continuation of construction of the largest Centre for Science and Research in Central and Eastern Europe together with a great financial resultRead more »